Advertisement

Topics

US FDA approves Seattle Genetics' Adcetris in combo with CHP chemotherapy for previously untreated sALCL/other CD30─expressing PTCL

13:17 EST 20 Nov 2018 | PharmaBiz

Seattle Genetics, Inc announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the US Food and Drug Administration

Original Article: US FDA approves Seattle Genetics' Adcetris in combo with CHP chemotherapy for previously untreated sALCL/other CD30─expressing PTCL

NEXT ARTICLE

More From BioPortfolio on "US FDA approves Seattle Genetics' Adcetris in combo with CHP chemotherapy for previously untreated sALCL/other CD30─expressing PTCL"

Advertisement
Quick Search
Advertisement
Advertisement